Vitalibis, Inc.

Vitalibis, Inc.

VCBDQ
Vitalibis, Inc.US flagOther OTC
0.00
USD
+0.00
- -
227,440.00Market Cap
No data availableFinancial data will appear here once available

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Company Description

APIChatGPT
CEO
Steven P. Raack
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
3960 Howard Hughes Parkway Las Vegas NV United States of America 89169
IPO Date
Feb 22, 2018
Business
Vitalibis, Inc. (VCBDQ) operates as a technology-based formulator and marketer of phytocannabinoid-rich hemp products containing cannabidiol; it offers personal care items such as cold-processed skin care and body care products; nutritional supplements including organic certified products and water-soluble hemp powder; and CBD oil extracts targeted at the medicinal cannabis and consumer wellness industries primarily in the United States. Founded in 2014 and headquartered in Las Vegas, Nevada, the company, formerly known as Sheng Ying Entertainment Corp. and Crowd 4 Seeds, Inc., rebranded to Vitalibis in February 2018 to focus on hemp-derived cannabinoid innovations. In recent developments, Vitalibis pursues an acquisition or merger with another company as of October 2025, while denying involvement in an unauthorized press release claiming such activities; it previously launched a gracefully-aging CBD skincare line including Re-Vitalizing Face Wash in January 2020, with no major funding rounds, partnerships, or expansions reported in 2024-2025.